|
|
||||||||
Ann Thorac Surg 1997;63:1138-1144
© 1997 The Society of Thoracic Surgeons
Departments of Cardiac Surgery, Anesthesiology, and Pediatric Cardiology, Charité, Humboldt-University Berlin, Berlin, and Helmholtz Institute, Aachen, Germany
Accepted for publication November 1, 1996.
| Abstract |
|---|
|
|
|---|
Methods. The pneumatic paracorporeal ventricular assist device has three left ventricular sizes (10-, 25-, and 60-mL maximum stroke volume) and three right ventricular sizes (9, 22.5, and 54 mL) and can be operated effectively with up to 180 cycles/min. We used this device in 6 consecutive pediatric patients. Intention of treatment was to bridge to transplantation in 3 patients and to aid in recovery from a cardiac operation in 3. Age ranged from 5 days to 8 years.
Results. Two children died during assist, 2 were weaned from the system and discharged home, and 2 had successful transplantation. During assist, laboratory variables indicative of impaired renal, hepatic, or pulmonary function normalized or showed a trend toward normalization. Both deaths were related to infection.
Conclusions. With the new MEDOS HIA-VAD ventricular assist device system, pediatric mechanical cardiac assist can be performed successfully. It requires timely implantation, careful monitoring, and adequate size-matched devices.
| Introduction |
|---|
|
|
|---|
Mechanical circulatory assist with ventricular assist devices (VADs) in infants and children is still evolving. Although the need of pediatric cardiac assist is growing because of the complexity of the lesions operated on today and because of the success of pediatric cardiac transplantation, a pediatric support system covering the wide demands of this heterogeneous patient group was not available until very recently. We evaluated the newly developed pediatric MEDOS HIA-VAD in 6 consecutive patients.
| Material and Methods |
|---|
|
|
|---|
The system is available in three left ventricular sizes of 10-, 25-, and 60-mL maximum stroke volume (Fig 1
). Ventricles that are 10% smaller, namely, 9, 22.5, and 54 mL, are intended for right ventricular support if the need of biventricular support should arise. The ventricles are made of polyurethane with a double-layer inner, displacement membrane and are pneumatically driven. The polyurethane three-leaflet valves are incorporated seamlessly, and the ventricles are totally transparent to allow visual control of filling and emptying and observation of any air during installment of the system or clot formation during prolonged pumping. The design of the ventricles was optimized by the demands of fluid dynamics, and the valve design follows valvular geometry and physical demands. This led to leaflets 0.2 mm thick and allows very low opening and closing pressures [2]. Systolic transvalvular gradients are low, and rapid closure of the valve minimizes regurgitant flow. The ventricles are intended for paracorporeal use.
|
|
|
| Patient Population |
|---|
|
|
|---|
|
| Surgical Techniques |
|---|
|
|
|---|
| Anticoagulation and Antibiotics |
|---|
|
|
|---|
Antibiotic treatment consisted initially of routine institutional postcardiotomy treatment with penicillin. On the basis of blood and urine cultures and wound, tracheal, throat, or fecal swabs, the regimen was changed later. The exit points of the VAD tubing were dressed daily under sterile conditions with povidone-iodine ointment.
| Respirator Treatment and Supportive Measures |
|---|
|
|
|---|
For older children, sitting in bed and walking in the room were strongly recommended. Infants were allowed to be on the parent's or nurse's arm after extubation, and breast feeding was recommended, when appropriate.
| Results |
|---|
|
|
|---|
The VAD sizes, duration of support, survival, and complications are summarized in Table 2
. Anticoagulation was maintained with heparin with the aim of a partial thromboplastin time higher than 50 seconds; or an activated clotting time in the range of 180 to 220 seconds. Bleeding requiring reexploration, thromboembolic complications, or both occurred in 2 patients. One 5-year-old patient required several reexplorations during support and underwent successful transplantation after 5 days. The other patient, a 5-month-old infant, sustained a transient minor stroke 15 days after implantation of the device. One day earlier, the leukocyte count increased and the desired activated clotting time could not be reliably maintained, which resulted in an increased need of heparin. Thrombi were visible in one sinus of the outflow valve, which prompted a change in the ventricle and increased anticoagulation. One day later, massive retroperitoneal bleeding led to surgical exploration, and a bleeding site at the femoral artery from a previous pressure-monitoring line was identified. The child died of profound bleeding 1 day later.
|
|
|
|
| Comment |
|---|
|
|
|---|
In infants and children, extracorporeal membrane oxygenation has been shown to be more successful than in adults [6]. However, ECMO requires a complex setup, a variety of monitoring lines, and most often endotracheal intubation and allows no ambulation or other physical activity [79]. Continuous surveillance by trained personnel is mandatory. These limitations seem undesirable, especially in infants who are bridged to transplantation. Other systems that have been used in infants and children include centrifugal pumps for univentricular and biventricular support [10]. However, with full unloading of the heart, they do not permit pulsatile flow. Loss of pulsatility has been blamed for capillary leakage during prolonged pump runs [11, 12], and recovery of the heart may be improved by electrocardiogram-trigged counterpulsation of the device [13].
In addition, patients on centrifugal pumps are confined to bed. It would be difficult to mobilize and transport babies and small infants while they require a centrifugal pump. This can be accomplished much more easily when the pump is close to the body and wearable, as with pneumatically driven paracorporeal assist devices. Pneumatically driven paracorporeal pumps are in clinical use with the Thoratec system, but it is currently available only for adults. The pediatric MEDOS HIA-VAD described here is a commercially available system applicable to infants and allows matching the VAD size to the patient's need. The use of adult or intermediate-sized pneumatic ventricles in infants and children is associated with low pump rates and large stroke volumes. Slow operation of the pump, however, increases the thromboembolic risk [14].
Death in our series occurred only in combination with infection. Probably in 1 infant, infection triggered coagulation abnormalities resulting in thromboemboli and subsequent bleeding. This pathophysiologic pathway has been described previously by Didisheim and associates [15] and recently by Copeland and co-workers [16] in a patient with an implantable artificial heart. Because infection was the most common cause of death in that series, we increased microbiologic surveillance, and now we isolate and monitor these patients as we do transplant patients. The longest support time for a survivor was 9 days 8 hours, after which the child underwent successful transplantation. In longer runs, prevention of infection and adequate anticoagulation require utmost attention. This is very important, as patients who do not recover after a few days may become transplant candidates.
In this small study, we have shown that pediatric left VAD or right VAD support for postcardiotomy failure or as a bridge to transplantation can be performed in infants and children with a reasonable salvage rate. The system described has some unique features, including VAD sizes that can accommodate small babies as well as adults. Further clinical research and application of the system for biventricular support are in progress.
| Footnotes |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
Related Article
This article has been cited by other articles:
![]() |
K. Januszewska, E. Malec, J. Birnbaum, M. Loeff, R. Sodian, C. Schmitz, H. Netz, and B. Reichart Ventricular assist device as a bridge to heart transplantation in children Interactive CardioVascular and Thoracic Surgery, November 1, 2009; 9(5): 807 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Imamura, A. M. Dossey, P. Prodhan, M. Schmitz, E. Frazier, U. Dyamenahalli, A. Bhutta, W. R. Morrow, and R. D.B. Jaquiss Bridge to Cardiac Transplant in Children: Berlin Heart versus Extracorporeal Membrane Oxygenation. Ann. Thorac. Surg., June 1, 2009; 87(6): 1894 - 1901. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hetzer, E. V. Potapov, B. Stiller, Y. Weng, M. Hubler, J. Lemmer, V. Alexi-Meskishvili, M. Redlin, F. Merkle, F. Kaufmann, et al. Improvement in survival after mechanical circulatory support with pneumatic pulsatile ventricular assist devices in pediatric patients. Ann. Thorac. Surg., September 1, 2006; 82(3): 917 - 924. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. McMahon, C. van Doorn, M. Burch, P. Whitmore, S. Neligan, P. Rees, R. Radley-Smith, A. Goldman, K. Brown, G. Cohen, et al. Improved early outcome for end-stage dilated cardiomyopathy in children J. Thorac. Cardiovasc. Surg., January 1, 2004; 126(6): 1781 - 1787. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. W. Duncan Mechanical circulatory support for infants and children with cardiac disease Ann. Thorac. Surg., May 1, 2002; 73(5): 1670 - 1677. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. W. Duncan, D. J. Bohn, A. M. Atz, J. W. French, P. C. Laussen, and D. L. Wessel Mechanical circulatory support for the treatment of children with acute fulminant myocarditis J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 440 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y. Schure, P. C. Laussen, and F. X. McGowan JR Mechanical Cardiopulmonary Support of Infants and Children With Congenital Heart Disease Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2001; 5(1): 46 - 54. [Abstract] [PDF] |
||||
![]() |
M. A. Acker Mechanical circulatory support for patients with acute-fulminant myocarditis Ann. Thorac. Surg., March 1, 2001; 71 (2007): S73 - S76. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Jacobs, J. W. Ojito, T. W. McConaghey, B. D. Boden, A. C. Chang, A. Aldousany, E. M. Zahn, and R. P. Burke Rapid cardiopulmonary support for children with complex congenital heart disease Ann. Thorac. Surg., September 1, 2000; 70(3): 742 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Thuaudet The Medos ventricular assist device system Perfusion, July 1, 2000; 15(4): 337 - 343. [PDF] |
||||
![]() |
C. Schmitz, A. Welz, O. Dewald, R. Kozlik-Feldmann, H. Netz, and B. Reichart Switch from a BIVAD to a LVAD in a boy with Kawasaki disease Ann. Thorac. Surg., April 1, 2000; 69(4): 1270 - 1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
B Stiller, I Dahnert, Y G Weng, E Hennig, R Hetzer, and P E Lange Children may survive severe myocarditis with prolonged use of biventricular assist devices Heart, August 1, 1999; 82(2): 237 - 240. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hetzer, M. Loebe, E. V. Potapov, Y. Weng, B. Stiller, E. Hennig, V. Alexi-Meskishvili, and P. E. Lange Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children Ann. Thorac. Surg., November 1, 1998; 66(5): 1498 - 1506. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Westaby, T. Katsumata, R. Houel, R. Evans, D. Pigott, O. H. Frazier, and R. Jarvik Jarvik 2000 Heart : Potential for Bridge to Myocyte Recovery Circulation, October 13, 1998; 98(15): 1568 - 1574. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Shum-Tim, B. W. Duncan, V. Hraska, I. Friehs, T. Shin'oka, and R. A. Jonas Evaluation of a Pulsatile Pediatric Ventricular Assist Device in an Acute Right Heart Failure Model Ann. Thorac. Surg., November 1, 1997; 64(5): 1374 - 1380. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |